Showing 4501-4510 of 6036 results for "".
- EyeCare Partners Expands Footprint in Oklahoma with Retinal Associates of Oklahomahttps://modernod.com/news/eyecare-partners-expands-footprint-in-oklahoma-with-retinal-associates-of-oklahoma/2481328/EyeCare Partners (ECP) announced that it has expanded its presence in Oklahoma through a partnership with Retinal Associates of Oklahoma (RAO). Terms of the deal were not disclosed. The ECP network welcomes Darin R. Haivala, MD, and Rob
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Eye Care Divisionhttps://modernod.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/Viatris announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7. Former Oyster Point Pharma CEO, Jeffrey Nau, PhD, MMS, will lead the new di
- Mobius Therapeutics Granted New US Patent for Injected Ophthalmic Mitomycin-Chttps://modernod.com/news/mobius-therapeutics-granted-new-us-patent-for-injected-ophthalmic-mitomycin-c/2481319/Mobius Therapeutics has been issued US Patent #11,540,977, "Injection Apparatus and Method of Use," protecting future applications of Mitosol, Mobius’ flagship product, particularly versus compounded, unapproved copies of Mitosol. “This is an important ad
- Elios Vision Announces Registration of Elios in the United Kingdomhttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-the-united-kingdom/2481318/Elios, a technology used to treat glaucoma at the same time as cataract surgery, is now registered for use in the United Kingdom, according to Elios Vision. The Elios does not require an implant and is designed to provide long-lasting results that may free patients and th
- Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directorshttps://modernod.com/news/iveric-bio-announces-the-addition-of-pravin-u-dugel-md-to-its-board-of-directors/2481317/Iveric bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the company’s business strategy and in overseeing the development and regulatory submission
- Bausch + Lomb and Glaucoma Research Foundation Announce Launch of "Screen, Protect, Cure" Campaignhttps://modernod.com/news/bausch-lomb-and-glaucoma-research-foundation-announce-launch-of-screen-protect-cure-campaign/2481316/Bausch + Lomb and Glaucoma Research Foundation (GRF) announced the US launch of "Screen, Protect, Cure," a campaign designed to provide educational resources and raise awareness of glaucoma during Glaucoma Awareness Month. “We are proud to collaborate with Glau
- Opus Genetics Acquires Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases from Iveric Biohttps://modernod.com/news/opus-genetics-acquires-rights-to-two-gene-therapy-product-candidates-for-inherited-retinal-diseases/2481311/Opus Genetics announced it has acquired the rights to two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio. Opus will develop the novel gene therapy candidates to address bestrophin-1(BEST1)-related inherited retinal diseases a
- Study Identifies a Signaling Cascade Behind Retina Regeneration in Zebrafishhttps://modernod.com/news/study-identifies-a-signaling-cascade-behind-retina-regeneration-in-zebrafish/2481309/Experts at University of Michigan Medical School are investigating how Muller glial cells, responsible for regenerating a damaged zebrafish retina, acquire stem cell properties with the hope of eventually developing techniques to encourage human retinas to regenerate. Building
- Outlook Therapeutics Announces Validation of Marketing Authorization Application by the EMA for ONS-5010 for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-validation-of-marketing-authorization-application-by-the-european-medicines-agency-for-ons-5010-as-a-treatment-for-wet-amd/2481308/Outlook Therapeutics announced the validation of its marketing authorization application (MAA) by the European Medicines Agency (EMA) for ONS-5010 / Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degener
- Melt Pharmaceuticals’ MELT-300 Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Studyhttps://modernod.com/news/melt-pharmaceuticals-melt-300-achieves-primary-sedation-endpoint-in-phase-2-pivotal-efficacy-and-safety-study/2481307/Melt Pharmaceuticals announced topline results of its phase 2 pivotal efficacy and safety study for its lead product candidate, MELT-300, a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery. Based on the outcome of the MELT-300 data, the